Invited article: human natural autoantibodies in the treatment of neurologic disease.
about
Current Concepts in Multiple Sclerosis: Autoimmunity Versus OligodendrogliopathyEnhancing CNS repair in neurological disease: challenges arising from neurodegeneration and rewiring of the networkAntibody-Mediated Oligodendrocyte Remyelination Promotes Axon Health in Progressive Demyelinating DiseaseSurface plasmon resonance for high-throughput ligand screening of membrane-bound proteinsMyelin recovery in multiple sclerosis: the challenge of remyelinationMethod of identifying natural antibodies for remyelination.Human-derived natural antibodies: biomarkers and potential therapeuticsRole of γδ T cells in antibody production and recovery from SFV demyelinating diseaseA human IgM signals axon outgrowth: coupling lipid raft to microtubules.A single dose of a neuron-binding human monoclonal antibody improves brainstem NAA concentrations, a biomarker for density of spinal cord axons, in a model of progressive multiple sclerosis.A natural human IgM that binds to gangliosides is therapeutic in murine models of amyotrophic lateral sclerosis.Therapeutics to promote CNS repair: a natural human neuron-binding IgM regulates membrane-raft dynamics and improves motility in a mouse model of multiple sclerosis.A monoclonal natural human IgM protects axons in the absence of remyelinationMolecular and immunogenic features of myelin lipids: incitants or modulators of multiple sclerosis?Inflammation in neurodegenerative diseases.Pathogenic and physiological autoantibodies in the central nervous system.The Role of 3-O-Sulfogalactosylceramide, Sulfatide, in the Lateral Organization of Myelin Membrane.
P2860
Q22252578-35F6E6C4-90FC-4770-85FE-82A1348434ABQ24630696-35BDE48F-4C68-4B1B-A99B-6622D8BDD772Q28080515-7613EE05-E801-4A98-AA13-2CE2106C8363Q30887281-F276D215-A46A-4647-BD8D-4C94C6FD5059Q33772195-7F81444A-0689-452E-BFD7-0E4C0F24115EQ33939608-FFADD120-606F-4C5B-B92B-AEAF5E7B57E2Q35064053-8244B1BD-67C6-4DB4-AA2D-50DD34E77655Q35175989-1D59C455-93AB-42C5-A51D-C97830A8A9FDQ35209531-3B428650-A220-49C3-B762-8B23B7D16FD2Q35564304-D7C363E9-7817-4315-937D-ACD12D74ADE7Q35923499-9A489241-4936-4216-88DE-F305CAD4567FQ36542427-B7B00433-A86E-4BDE-91A3-BE247495AC05Q36851038-9642B3AA-8671-49B6-9C8A-06B6E6E50C73Q37582663-FEF186DC-C213-4052-803E-6D041ACE45E7Q37766302-6E8ABA95-8B1D-4305-9647-80C918372380Q38020957-13DE097C-EF24-455D-8AC4-CF138A969517Q38626495-B8663DA0-644F-406B-8CC8-10F1688DC516
P2860
Invited article: human natural autoantibodies in the treatment of neurologic disease.
description
2009 nî lūn-bûn
@nan
2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Invited article: human natural autoantibodies in the treatment of neurologic disease.
@ast
Invited article: human natural autoantibodies in the treatment of neurologic disease.
@en
type
label
Invited article: human natural autoantibodies in the treatment of neurologic disease.
@ast
Invited article: human natural autoantibodies in the treatment of neurologic disease.
@en
prefLabel
Invited article: human natural autoantibodies in the treatment of neurologic disease.
@ast
Invited article: human natural autoantibodies in the treatment of neurologic disease.
@en
P2860
P1433
P1476
Invited article: human natural autoantibodies in the treatment of neurologic disease.
@en
P2093
Arthur E Warrington
Larry R Pease
P2860
P304
P356
10.1212/01.WNL.0000345662.05861.E4
P407
P577
2009-04-01T00:00:00Z